

REFERENCES

1. World Health Organization (WHO): *World Malaria Report 2017*. Geneva, Switzerland: WHO; 2017.
2. Barber BE, Rajahram GS, Grigg MJ, William T, Anstey NM: World malaria report: time to acknowledge *Plasmodium knowlesi* malaria. *Malaria J* 16: 135, 2017. [PMID: 28359340]
3. Mace KE, Arguin PM: Malaria surveillance—United States, 2014. *MMWR Surveillance Summaries*. *MMWR Morb Mortal Wkly Rep* 66(12): 1, 2017. [PMID: 28542123]
4. Centers for Disease Control and Prevention: *CDC Yellow Book 2018* (CDC Health Information for International Travel 2018). Atlanta, GA: Department of Health and Human Services, Public Health Service; 2018.
5. World Health Organization (WHO): *International Travel and Health*, 2018. Geneva, Switzerland: WHO; 2018.
6. Woodrow CJ, White NJ: The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread. *FEMS Microbiol Rev* 41(1): 34, 2017. [PMID: 27613271]
7. Baird JK: Chloroquine resistance in *Plasmodium vivax*. *Antimicrob Agents Chemother* 48: 4075, 2004. [PMID: 15504824]
8. Greenwood BM, Bojang K, Whitty CJ, Targett GA: Malaria. *Lancet* 365: 1487, 2005. [PMID: 15850634]
9. Koram K, Molyneux ME: When is “malaria” malaria? The different burdens of malaria infection, malaria disease and malaria-like illnesses, in Breman JG, Alilio MS, White NJ (eds): *Defining and Defeating the Intolerable Burden of Malaria: III. Progress and Perspectives*. *Am J Trop Med Hyg* 77(suppl): 1, 2007. [PMID: 18165468]
10. Beare NA, Taylor TE, Harding SP, Lewallen S, Molyneux ME: Malarial retinopathy: a newly established diagnostic sign in severe malaria. *Am J Trop Med Hyg* 75: 790, 2006. [PMID: 17123967]
11. Phillips A, Bassett P, Zeki S, et al: Risk factors for severe disease in adults with falciparum malaria. *Clin Infect Dis* 48: 871, 2009. [PMID: 19243243]
12. Dorsey G, Ghandhi M, Oxygi JH, et al: Difficulties in the prevention, diagnosis and treatment of imported malaria. *Arch Intern Med* 160: 2505, 2000. [PMID: 10979063]
13. White NJ: The treatment of malaria. *N Engl J Med* 335: 800, 1996. [PMID: 8703186]
14. Bisoffi Z, Gobbi F, Angheben A, Van den Ende J: The role of rapid diagnostic tests in managing malaria. *PLoS Med* 6: e1000063, 2009. [PMID: 19399160]
15. <https://www.who.int/malaria/areas/treatment/overview/en/> (World Health Organization: Overview of malaria treatment. Geneva: World Health Organization, 2018.) Accessed January 28, 2019.
16. http://www.cdc.gov/malaria/diagnosis_treatment/index.html. (Centers for Disease Control and Prevention: Treatment of Malaria: Guidelines For Clinicians [United States]). Accessed January 28, 2019.
17. <http://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf>. (Centers for Disease Control and Prevention: Malaria treatment table.) Accessed January 28, 2019.
18. <https://www.who.int/malaria/publications/atoz/policy-brief-single-dose-primaquine-pf/en/> (World Health Organization: WHO policy brief on single-dose primaquine as gametocytocide in *Plasmodium falciparum* malaria.) Accessed January 28, 2019.
19. Dondorp A, Nosten F, Stepniewska K, et al: Artesunate versus quinine for treatment of severe falciparum malaria: a randomized trial. *Lancet* 366: 717, 2005. [PMID: 16125588]
20. Dondorp AM, Fanello CI, Hendriksen IC, et al: Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. *Lancet* 376: 1647, 2010. [PMID: 21062666]
21. Birbeck GL, Molyneux ME, Kaplan PW, et al: Blantyre Malaria Project Epilepsy Study (BMPES) of neurological outcomes in retinopathy-positive paediatric cerebral malaria survivors: a prospective cohort study. *Lancet Neurol* 9: 1173, 2010. [PMID: 21056005]